News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1Bitget UEX Daily | Trump Claims Iran Requested Delay in Strikes; US Stocks Post Largest Drop Since US-Iran Conflict Began; Apple Opens Siri to External AI (March 27, 2026)2US-Iran Tensions Latest: Diplomatic Deadlock Drives Market Fluctuations as Trump Prolongs Suspension of Attacks on Energy Facilities3Bitcoin gained 655% the last time this supply in profit metric dropped to 50%
Buyers flee Japanese debt as Takaichi hits the ground spending
101 finance·2026/01/20 11:57
Netflix Earnings to Highlight Core Business as Warner Dispute Unfolds
101 finance·2026/01/20 11:45
Quant: Are long-term holders positioning for a larger move? Assessing…
AMBCrypto·2026/01/20 11:33
US IT hardware stocks fall as Morgan Stanley turns cautious on sector
101 finance·2026/01/20 11:30
USD: US-EU trade disputes spark risk aversion in markets – BBH
101 finance·2026/01/20 11:27
US Dollar weakens amid Greenland tariff uncertainty – MUFG
101 finance·2026/01/20 11:27
Disney succession: A look inside the hunt for Bob Iger's successor as CEO
101 finance·2026/01/20 11:21
Ethereum Price Prediction: ETH Cooldown Continues as Leverage Eases to $40.3B
CoinEdition·2026/01/20 11:18
Ethiopia Plans State-Backed Bitcoin Mining Using Hydropower
Cryptotale·2026/01/20 11:15
Hong Kong Securities Group Opposes Stricter Crypto Licensing Rules for Asset Managers.
Coinspeaker·2026/01/20 11:15
Flash
19:32
Eli Lilly announced that its combination therapy of Taltz and Zepbound achieved the primary endpoint and all key secondary endpoints in a 36-week study period, with data showing that this combination therapy was statistically significantly superior to Taltz monotherapy.This groundbreaking achievement highlights the synergistic effect of combination therapy, providing new clinical evidence for the treatment of related diseases. A comprehensive analysis of the research data will further support the prospects for the application of this therapy.
19:32
Incyte presented the latest positive 54-week data on its investigational drug Povorcitinib for the treatment of hidradenitis suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting.These delayed but important breakthrough research results further validate the long-term efficacy and safety of this therapy, bringing new hope to patients.
19:31
MoonLake Immunotherapeutics officially released the 40-week key data from the phase III clinical trial of its innovative drug Sonelokimab for the treatment of moderate to severe hidradenitis suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting.The results announced this time further validate the drug’s long-lasting efficacy and favorable safety profile, offering new hope for patients’ treatment.
Trending news
MoreIncyte presented the latest positive 54-week data on its investigational drug Povorcitinib for the treatment of hidradenitis suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting.
MoonLake Immunotherapeutics officially released the 40-week key data from the phase III clinical trial of its innovative drug Sonelokimab for the treatment of moderate to severe hidradenitis suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting.
News